Press release
Key Trends Shaping the Future Glioblastoma Multiforme Market From 2025-2034: Advancements In CAR T-Cell Therapies For Glioblastoma Multiforme Treatment
Glioblastoma Multiforme Market
The growing number of brain disorder cases is anticipated to boost the glioblastoma multiforme market in the coming years. A brain disorder is a condition that affects the brain's structure or function, leading to cognitive, emotional, or physical difficulties. The rise in brain disorder cases is attributed to factors such as an aging population, longer life expectancy, lifestyle changes, and better diagnostic technologies. Understanding these disorders advances research on glioblastoma multiforme (GBM), which leads to improved early detection, novel treatments, and better patient outcomes. By examining neurological diseases, researchers can identify genetic and molecular factors contributing to GBM development. For example, in February 2025, Dementia Australia, a non-profit organization, reported that around 433,300 Australians were living with dementia, with that number projected to increase to 812,500 by 2054. Moreover, younger-onset dementia will affect approximately 29,000 people in 2025, with projections rising to 41,000 by 2054. As a result, the rising prevalence of brain disorders will drive the growth of the glioblastoma multiforme market.
Get Your Glioblastoma Multiforme Market Report Here:
https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report
What is the future CAGR of the glioblastoma multiforme market, and how will it impact industry expansion?
The glioblastoma multiforme market has grown strongly, increasing from $2.50 billion in 2024 to $2.71 billion in 2025 at a CAGR of 8.3%. Key growth factors include a rising incidence of glioblastoma multiforme, improvements in healthcare infrastructure, increased awareness, greater access to advanced therapies, and an aging population.
The glioblastoma multiforme market is expected to grow steadily, reaching $3.69 billion by 2029 at a CAGR of 8.1%. Contributing factors include a rising number of brain and nervous system cancer cases, growing acceptance of surgical techniques, increased disease awareness, early diagnosis initiatives, and a surge in R&D activities. Emerging trends include advancements in medical technology, improvements in imaging techniques, the expansion of personalized medicine, AI-driven diagnostics, and continued progress in scientific and technological research.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21191&type=smp
What are the most significant trends transforming the glioblastoma multiforme market today?
In the glioblastoma multiforme (GBM) market, companies are advancing therapies like CAR T-cell treatments to meet the needs of patients with aggressive cancers. CAR T-cell therapies modify a patient's own T-cells to target cancer cells more effectively. In June 2023, Chimeric Therapeutics Limited, an Australia-based biotech company, launched a Phase IB clinical trial of CHM 1101 (CLXT CAR T) therapy for recurrent or progressive glioblastoma multiforme. The trial is evaluating the safety and efficacy of the treatment, and initial Phase 1a results have shown disease stability, with plans to proceed to a Phase 2 trial based on the findings.
Which key market segments comprise the glioblastoma multiforme market and drive its revenue growth?
The glioblastoma multiforme market covered in this report is segmented -
1) By Drug Class: Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes
2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI), Computed Tomography Scan (CT Scan), Biopsy, Other Diagnostic Tools
3) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field Therapy, Other Treatment Types
4) By End-User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Chemotherapy Agents: Alkylating Agents, Platinum-Based Agents, Antimetabolites
2) By Temozolomide: Branded (Temodar), Generic Temozolomide
3) By Carmustine: Injectable Carmustine, Carmustine Wafers (Gliadel)
4) By Lomustine: Branded (Gleostine), Generic Lomustine
5) By Other Drug Classes: Targeted Therapy, Immunotherapy, Tumor-Treating Fields (TTF) Therapy
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21191
What regions are at the forefront of glioblastoma multiforme market expansion?
North America was the largest region in the glioblastoma multiforme market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Who are the leading players fueling growth in the glioblastoma multiforme market?
Major companies operating in the glioblastoma multiforme market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, VBI Vaccines Inc.
Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21191&type=smp
What Is Covered In The Glioblastoma Multiforme Global Market Report?
•Market Size Forecast: Examine the glioblastoma multiforme market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the glioblastoma multiforme market for a structured understanding.
•Key Players Overview: Analyze major players in the glioblastoma multiforme market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the glioblastoma multiforme market.
•Segment Contributions: Evaluate how different segments drive overall growth in the glioblastoma multiforme market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the glioblastoma multiforme market.
•Industry Challenges: Identify potential risks and obstacles affecting the glioblastoma multiforme market.
•Competitive Landscape: Review strategic developments in the glioblastoma multiforme market, including expansions, agreements, and new product launches.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Key Trends Shaping the Future Glioblastoma Multiforme Market From 2025-2034: Advancements In CAR T-Cell Therapies For Glioblastoma Multiforme Treatment here
News-ID: 3934708 • Views: …
More Releases from The Business Research Company
Seed Treatment Fungicides Market to Grow at 9.3% CAGR, Reaching $3.15 Billion by …
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
Seed Treatment Fungicides Market Outlook: How is the Market Expected to Grow by 2025?
Over the past few years, the market for seed treatment fungicides has seen robust growth. Its market value is projected to rise from $2.07 billion in 2024 to $2.21 billion in 2025, signifying a compound annual…
Rheology Modifiers Market Growth to be Driven by Emerging Trends | $10.92 Billio …
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
What is the Projected Market Size of the Rheology Modifiers Industry?
There has been a consistent expansion in the size of the rheology modifiers market in the past few years. The market, which was worth $8.59 billion in 2024, is projected to increase to $8.89 billion in 2025, demonstrating a compound…
Polyurethane Foam Market to Record 8.4% CAGR Growth Through 2029 | Global Analys …
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
Polyurethane Foam Market Outlook: How is the Market Expected to Grow by 2025?
In recent years, the size of the polyurethane foam market has experienced substantial growth. It is projected to increase from a value of $54.27 billion in 2024 to $57.26 billion in 2025, indicating a compound annual growth…
Pharmaceutical Intermediates Market Size to Reach $46.04 Billion by 2029 | Growt …
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
What is the Projected Market Size of the Pharmaceutical Intermediates Industry?
There has been consistent growth in the market size of pharmaceutical intermediates over the past few years. The market is predicted to increase from a value of $33.37 billion in 2024, up to $34.95 billion in 2025, with a compound…
More Releases for Glioblastoma
Glioblastoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Glioblastoma Pipeline Insight, 2024," report provides comprehensive insights about 195+ companies and 210+ pipeline drugs in Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Glioblastoma Pipeline Report
* DelveInsight's Glioblastoma pipeline report depicts…
Glioblastoma Multiforme Market Insights, Forecast to 2031
"Glioblastoma Multiforme Market 2024,"
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Glioblastoma Multiforme market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market shares held by major segments within the Glioblastoma Multiforme industry, providing stakeholders with a nuanced perspective on market…
Beyond Bravery - Bill Fitzpatrick's Fight Against Glioblastoma
Bill Fitzpatrick Jr, a retired sales professional from GE, has recently ventured into the world of writing with his debut book. Inspired by his experiences during taking care of his wife, who had Glioblastoma, Bill felt the need to share his journey and provide support to other families navigating similar challenges. In this article, we will dive into Bill's background, his motivation for becoming an author, details about his latest…
Recurrent Glioblastoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Recurrent Glioblastoma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Recurrent Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Recurrent Glioblastoma Pipeline Report
DelveInsight's Recurrent Glioblastoma…
Revolutionizing Glioblastoma Treatment Strategies: A Deep Dive into the Glioblas …
The Glioblastoma Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Glioblastoma treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the Glioblastoma pipeline landscape and fostering the potential growth of Glioblastoma therapeutic advancements.
Key Takeaways from the Glioblastoma Pipeline Report
• DelveInsight's Glioblastoma pipeline report depicts a robust space with 195+ active players…
2019 - 2025 Glioblastoma Multiforme Treatment Market | GBM Market
Global Glioblastoma Multiforme Treatment Market, Its Market Trends And Analysis
Glioblastoma multiforme is the high-grade glioma and potent malignant brain tumor that affects glial cells. Glioblastoma multiforme contains the complexly differentiated neoplastic astrocytes which are the subtype of central nervous system. Glioblastoma multiforme is different from the anaplastic astrocytoma due to the presence of hyperplastic blood vessels and necrotic tissue.
Request Sample Report:
https://precisionbusinessinsights.com/request-sample?product_id=16248
The global glioblastoma multiforme treatment market is…
